DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

Glutathione
ABC transporters and, 105t
in acetaminophen toxicity, 76, 76f
Glutathione conjugation, 135–136
Glutathione-S-transferases (GSTs),
125, 125t, 135–136
polymorphisms, 159t
Glutathionylation, 128t
Glutathione conjugation, variability in,
148
Glyburide, 1257t
pharmacokinetics of, 1847t
Glycerin, 681
pharmacology of, 681t
structure of, 681t
Glyceryl trinitrate, 759
chemistry of, 753
Glycine, in central nervous system, 379
Glycogen storage disease, 103t
Glycoholate, ABC transporters and,
105t
Glycopeptides, 1539–1542
Glycoprotein (GP) IIb/IIIa inhibitors,
antiplatelet effects, 849
Glycoprotein hormones, 1106t,
1117–1120
Glycosuria, angiotensin converting
enzyme inhibitors and, 736
Glycylcyclines
absorption of, 1523
antimicrobial activity of, 1521–1523
distribution of, 1524
excretion of, 1524
mechanism of action of, 1523
resistance to, 1523
sources and chemistry of, 1521
therapeutic uses of, 1524–1526
GLYNASE (glyburide), 1257t
GMP-dependent protein kinase
(PKG), 56
Goldman-Hodgkin-Katz equation, 93
Gold therapy, ocular effects of, 1793
Golimumab, 994t
Gonadal dysgenesis, 1838
GONADERELIN (gonadotropin-releasing
hormone), 1764t
Gonadorelin acetate, 1119t
Gonadorelin hydrochloride, 1119t
Gonadotropic hormones, secretion of,
regulation of GnRH release
and, 1119t
Gonadotropin(s), for fertility induction,
1843–1844, 1844f
adverse effects and side effects of,
1845
Gonadotropin-releasing hormone
(GnRH)
analogs of, 1668t–1670t
structure and relative potency of,
1119t
clinical uses of, 1121–1123
diagnostic uses of, 1121
secretion of, 1119t
structure and relative potency of,
1119t
structure of, 1764t
Gonadotropin-releasing hormone
(GnRH) agonists
depot forms, 1765
for endometriosis, 1840
for hirsutism, 1841
in IVF protocol, 1843
for prostate cancer therapy,
1763–1765
structures, 1764t
Gonadotropin-releasing hormone
(GnRH) antagonists
in IVF protocol, 1843
for prostate cancer therapy,
1763–1765
structures, 1764t
Gonococcal infections
drugs for, 1841, 1842t
penicillin for, 1486
Goserelin, 1119t, 1122, 1765
structure of, 1764t
Goserelinb, for endometriosis,
1840
Gout
acute
colchicine for, 995
prevention of, colchicine for,
995–996
treatment of, 1000
antihyperuricemic therapy, 1000
niacin and, 900
pathophysiology of, 994
pharmacotherapy of, 994–1000
clinical summary, 1000
recurrent attacks, prevention of,
1000
GPCR. See G protein-coupled
receptors (GPCR)
G6PD. See Glucose-6-phosphate
dehydrogenase (G6PD)
GPIIb/IIIa antagonists, features, 871t
G protein-coupled receptors (GPCR),
52–55
G proteins, 55, 205
activation of, 55
Graft-versus-host disease (GVHD)
IVIG for, 1827
tacrolimus for, 1822
Granulocyte colony-stimulating factor
(G-CSF), 1070t, 1074–1075,
1745, 1750
Granulocyte-macrophage colonystimulating
factor (GM-
CSF), 1070t, 1073–1074,
1745, 1750
in inflammation, 960, 961
Granuloma, dapsone for, 1823
Granuloma, drugs for, 1842t
Grapefruit juice, 139
Grepafloxacin, ABC transporters and,
105t
Griseofulvin, 1585–1586, 1817–1818
indications for, 1816t
for onychomycosis, 1818
for tinea capitis, 1818
Growth, thyroid hormone effects on,
1139–1140
Growth factors, signaling pathways,
1734, 1735f
Growth hormone (GH), 1106–1117,
1106t
human, for short stature, 1838
opioids and, 495
recombinant human, 1115–1117
GSK189245, 925
GSK239512, 925
GSTs. See Glutathione-S-transferases
(GSTs)
Guanabenz, 297
adverse effects and side effects of, 782
as antihypertensive agent, 774t,
781–782
Guanadrel, 782–783
adrenergic receptors and, 206t
as antihypertensive agent, 774t,
782–783
Guanfacine, 297
adverse effects and side effects of,
782
as antihypertensive agent, 774t,
781–782
Guanine nucleotide exchange factors
(GEFs), 56
Guanoxan, polymorphisms and
response to, 159t
Guanylate cyclase, soluble, 64–65
Guanylyl cyclase, direct activators of,
808
GVHD. See Graft-versus-host disease
(GVHD)
2031
INDEX